BCL2 and colorectal carcinoma: Following our preceding studies, and equipped with new and highly specific BH3-mimetics, the aim of this study was to further delineate the potential of targeting antiapoptotic BCL-2 proteins, especially BCL-XL, in the context of CRC treatment in terms of efficacy, toxicity and as a combinatorial approach with standard-of care therapeutic agents.